Home Shayne Heffernan on Investments Martin Shkreli Is Back With a Web3 Drug Discovery

Martin Shkreli Is Back With a Web3 Drug Discovery

by Natalies Edwards

Just out of prison, the former executive is launching a crypto-backed venture that tests the limits of his lifetime ban from the pharmaceutical industry. The creation of a blockchain-based Web3 drug discovery platform.

MARTIN SHKRELI—THE NOTORIOUS ex-pharmaceutical executive fresh from prison after his 2017 fraud conviction. Has announced his latest, eyebrow-raising venture this week. The creation of a blockchain-based Web3 drug discovery platform that traffics in his own cryptocurrency, MSI, aka Martin Shkreli Inu.

The platform is in its early-development phase which is called “Druglike”. According to a press release that circulated on July 25. Its goals are ostensibly lofty but the details are extremely sketchy. While Shkreli’s intentions have already drawn skepticism. It is also unclear whether the enterprise will run Shkreli afoul of his lifetime ban from the pharmaceutical industry. Which stemmed from the abrupt and callous 4,000 percent price hike of a life-saving drug that made him infamous.

Shkreli a cofounder of Druglike says the platform aims to make early-stage drug discovery more affordable and accessible.

“Druglike will remove barriers to early-stage drug discovery, increase innovation and allow a broader group of contributors to share the rewards,” Shkreli said in the press release. “Underserved and underfunded communities, such as those focused on rare diseases or in developing markets, will also benefit from access to these tools.”

Generally, early-stage drug development can sometimes involve virtual screens to identify potential drug candidates. In these cases, pharmaceutical scientists first identify a “target”—a specific compound or protein that plays a critical role in developing a disease or condition. Then researchers look for compounds or small molecules that could interfere with that target, sometimes binding or “docking” directly to the target in a way that keeps it from functioning.

Virtual Screening of Drug Candidates

That is where Shkreli’s Druglike is imagined to come in. Shkreli-associated Jason Sommer lays out some concepts for how the company’s platform would work. Essentially, it would use a decentralized computing network of task providers, solvers, and validators that would run and optimize the virtual screening of drug candidates. The white paper draws similarities to FoldIt. An online puzzle game that essentially uses distributed computing and crowdsourcing to fold proteins and predict their structures.

Druglike’s platform is preferred as incorporating blockchain concepts and cryptocurrency transactions when users complete tasks, such as docking screens. For instance, the paper describes a “proof-of-optimization” concept as a “novel” blockchain-based verification step. For screening work, similar to Bitcoin’s “proof-of-work” method.

“We propose a blockchain-based implementation of Proof-of-Optimization. Where a distributed ledger stores records of which proof solutions belong to which Solvers. Smart contracts allow secure distribution of rewards to the Solver who owns the verified proof,” Sommer writes in the paper.

The white paper only loosely describes these concepts, and it’s unclear how the cryptocurrency transactions will generate value. It remains unclear how the project will be funded, although an online exchange suggested that the company could look for venture capital financing.

In that conversation, he scoffed at the idea that the platform would breach his lifetime ban from the pharmaceutical industry. Saying that the project only involves developing software, not drugs. “Writing some code in Github and pressing ‘go’ does not make you a pharmaceutical company,” he said.

You may also like


Your Trusted Source for Capital Markets & Related News

© 2023 LiveTradingNews.com – For The Traders, By The Traders – All Right Reserved.

The information contained on this website shall not be construed as (i) an offer to purchase or sell, or the solicitation of an offer to purchase or sell, any securities or services, (ii) investment, legal, business or tax advice or an offer to provide such advice, or (iii) a basis for making any investment decision. An offering may only be made upon a qualified investor’s receipt not via this website of formal materials from the Knightsbridge an offering memorandum and subscription documentation (“offering materials”). In the case of any inconsistency between the information on this website and any such offering materials, the offering materials shall control. Securities shall not be offered or sold in any jurisdiction in which such offer or sale would be unlawful unless the requirements of the applicable laws of such jurisdiction have been satisfied. Any decision to invest in securities must be based solely upon the information set forth in the applicable offering materials, which should be read carefully by qualified investors prior to investing. An investment with Knightsbridge is not suitable or desirable for all investors; investors may lose all or a portion of the capital invested. Investors may be required to bear the financial risks of an investment for an indefinite period of time. Qualified investors are urged to consult with their own legal, financial and tax advisors before making any investment. Knightsbridge is a private investment firm that offers investment services to Qualified Investors, Members and Institutions ONLY. Qualified Investors are defined as individuals who have met those Qualifications in the relevant jurisdictions. Members are defined as individuals who have been accepted into the Knightsbridge membership program. Institutions are defined as entities such as banks, pension funds, and hedge funds. If you are not a Qualified Investor, Member or Institution, you are not eligible to invest with Knightsbridge. All investments involve risk, and there is no guarantee of profit. You may lose some or all of your investment. Past performance is not indicative of future results. Knightsbridge is not a registered investment advisor, and this disclaimer should not be construed as investment advice. Please consult with a qualified financial advisor before making any investment decisions. By accessing this website, you agree to the terms of this disclaimer. Thank you for your interest in Knightsbridge.